{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Conditioning&page=22",
    "query": {
      "condition": "Conditioning",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 564,
    "total_pages": 57,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Conditioning&page=23&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Conditioning&page=21&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T17:39:20.333Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01894477",
      "title": "Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia in Remission",
        "Chronic Myelomonocytic Leukemia",
        "Minimal Residual Disease",
        "Myelodysplastic Syndrome",
        "Myelodysplastic/Myeloproliferative Neoplasm",
        "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable"
      ],
      "interventions": [
        {
          "name": "Allogeneic Bone Marrow Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Treosulfan",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "Up to 70 Years"
      },
      "enrollment_count": 102,
      "start_date": "2013-11",
      "completion_date": "2022-06",
      "has_results": true,
      "last_update_posted_date": "2021-06-03",
      "last_synced_at": "2026-10-21T17:39:20.333Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01894477"
    },
    {
      "nct_id": "NCT00005922",
      "title": "Conditioning, the Placebo Effect, and Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Partial schedule of pharmacotherapeutic reinforcement",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Dose control for Arm B",
          "type": "DRUG"
        },
        {
          "name": "Standard pharmacotherapeutic protocol",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 138,
      "start_date": "2000-08",
      "completion_date": "2006-07",
      "has_results": false,
      "last_update_posted_date": "2013-09-24",
      "last_synced_at": "2026-10-21T17:39:20.333Z",
      "location_count": 2,
      "location_summary": "Palo Alto, California • Rochester, New York",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005922"
    },
    {
      "nct_id": "NCT01080196",
      "title": "Reducing Falls With RENEW in Older Adults Who Have Fallen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Muscle Atrophy",
        "Physical Deconditioning"
      ],
      "interventions": [
        {
          "name": "RENEW",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "65 Years to 95 Years"
      },
      "enrollment_count": 134,
      "start_date": "2008-04",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2022-06-21",
      "last_synced_at": "2026-10-21T17:39:20.333Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01080196"
    },
    {
      "nct_id": "NCT02713542",
      "title": "Autologous Conditioned Plasma (ACP) Intra-articular (IA) Injections for Knee Osteoarthritis (OA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Osteoarthritis"
      ],
      "interventions": [
        {
          "name": "ACP",
          "type": "DEVICE"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Arthrex, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 90,
      "start_date": "2016-07",
      "completion_date": "2018-08-30",
      "has_results": true,
      "last_update_posted_date": "2019-08-13",
      "last_synced_at": "2026-10-21T17:39:20.333Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • Ann Arbor, Michigan • Columbia, Missouri + 1 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Columbia",
          "state": "Missouri"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02713542"
    },
    {
      "nct_id": "NCT03367546",
      "title": "Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Thalassemia",
        "High Risk Hematologic Disorders",
        "Cerebral Adrenoleukodystrophy",
        "Inherited Metabolic Disorders"
      ],
      "interventions": [
        {
          "name": "Blood and Marrow Transplant",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "0 Years to 25 Years"
      },
      "enrollment_count": 5,
      "start_date": "2018-07-02",
      "completion_date": "2022-12-19",
      "has_results": false,
      "last_update_posted_date": "2024-07-12",
      "last_synced_at": "2026-10-21T17:39:20.333Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03367546"
    },
    {
      "nct_id": "NCT01596699",
      "title": "Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myeloid Malignancy",
        "Bone Marrow Failure Syndrome",
        "Transfusion-dependent Red Blood Cell (RBC) Defect",
        "Congenital Immunodeficiency",
        "Metabolic Disease",
        "Severe Immune Dysregulation"
      ],
      "interventions": [
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Clofarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "3 Months to 30 Years"
      },
      "enrollment_count": 16,
      "start_date": "2012-05-24",
      "completion_date": "2019-06",
      "has_results": true,
      "last_update_posted_date": "2020-02-26",
      "last_synced_at": "2026-10-21T17:39:20.333Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01596699"
    },
    {
      "nct_id": "NCT00143884",
      "title": "Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma, Low-Grade",
        "Lymphoma, Non-Hodgkin's",
        "Multiple Myeloma",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Reduced intensity conditioning",
          "type": "PROCEDURE"
        },
        {
          "name": "Prophylactic donor leukocyte infusions",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 30,
      "start_date": "2000-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2007-04-23",
      "last_synced_at": "2026-10-21T17:39:20.333Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00143884"
    },
    {
      "nct_id": "NCT04871607",
      "title": "Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Hodgkin Lymphoma",
        "Refractory Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Basiliximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Carmustine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Genetically Engineered Hematopoietic Stem Progenitor Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant Granulocyte Colony-Stimulating Factor",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Yttrium Y 90 Basiliximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2021-11-02",
      "completion_date": "2029-10-02",
      "has_results": false,
      "last_update_posted_date": "2025-12-04",
      "last_synced_at": "2026-10-21T17:39:20.333Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04871607"
    },
    {
      "nct_id": "NCT02989844",
      "title": "Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia (AML)",
        "Myelodysplastic Syndrome (MDS)"
      ],
      "interventions": [
        {
          "name": "N-803",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2017-04-12",
      "completion_date": "2022-08-31",
      "has_results": true,
      "last_update_posted_date": "2023-11-03",
      "last_synced_at": "2026-10-21T17:39:20.333Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02989844"
    },
    {
      "nct_id": "NCT06028828",
      "title": "Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allogeneic Hematopoietic Stem Cell Transplantation",
        "Allogeneic Stem Cell Transplantation",
        "Hematologic Malignancies"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 60,
      "start_date": "2023-09-11",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-02-02",
      "last_synced_at": "2026-10-21T17:39:20.333Z",
      "location_count": 1,
      "location_summary": "Orange, California",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06028828"
    }
  ]
}